Inositol News and Research

RSS

University of Leicester awarded BBSRC grant to explore three key areas that impact human health

The University of Leicester has been awarded over £1.5 million in order to advance knowledge and understanding in three key areas that impact on health.

5 Nov 2015

UCI scientists find potential biomarker for diagnosing certain forms of autism

By identifying a key signaling defect within a specific membrane structure in all cells, University of California, Irvine researchers believe, they have found both a possible reliable biomarker for diagnosing certain forms of autism and a potential therapeutic target.

22 Sep 2015

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $2.2 million by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to advance an innovative approach to the treatment of obesity, a serious health problem that affects more than one-third of all Americans.

28 May 2015

Studies reveal that dietary supplement can improve reproductive health

Current statistics on U.S. birth rates from the Centers for Disease Control and Prevention report a continued trend toward delayed motherhood. As fertility gradually declines in the 30s, particularly after age 35, the risk of experiencing difficulty conceiving may increase. In addition to age, there are other common reasons why women may experience difficulties conceiving, including: irregular ovulation cycles and poor egg quality, which may be associated with stress, lifestyle or poor diet.

13 Apr 2015

Transition announces positive results from ELND005 AME and renal clearance studies

Transition Therapeutics Inc. today announced results from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These studies, an absorption-metabolism-excretion ("AME") study and a renal clearance study, are specialized clinical pharmacology trials that are required by the United States Food and Drug Administration for the approval of most drugs in development.

26 Mar 2015

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time—and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations. In the case of blood stem cells (also called hematopoietic stem cells or HSCs), this can lead to blood cancers, a loss of blood cells and an impaired ability to fight disease.

26 Mar 2015

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

Stem cells can generate any type of cell in the body, but they are inactive most of the time--and for good reason. When stem cells become too active and divide too often, they risk acquiring cell damage and mutations.

24 Mar 2015

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Transition Therapeutics Inc. announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").

2 Mar 2015

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Study identifies novel gene that controls nerve conduction velocity linked with MS

A new study published in The American Journal of Pathology identifies a novel gene that controls nerve conduction velocity.

13 Aug 2014

Suppressing hyperactivity of calcium channels alleviates familial Alzheimer's disease

In 2008, researchers at the Perelman School of Medicine at the University of Pennsylvania showed that mutations in two proteins associated with familial Alzheimer's disease (FAD) disrupt the flow of calcium ions within neurons.

15 May 2014

Chinese herbal formula protects against hippocampal neurons death via non-classical estrogen pathway

Amyloid-β (Aβ) plaques and neurofibrillary tangles are the main pathological hallmarks of Alzheimer's disease, as well as the loss of neurons and synapses. recent reports have shown that estrogen exerts neuroprotective effects.

9 May 2014

New evidence indicates another risk factor for young adults consuming energy drinks

Newfound evidence indicates another risk factor for young adults consuming energy drinks. A research team representing six American universities found that the frequency of energy drink use is associated with increased odds of illicit prescription stimulant medication use.

3 Apr 2014

Study shows how Bcl-2 cancer-related protein signals cancer cells to live longer

A team of researchers from Case Western Reserve School of Medicine has discovered how the cancer-related protein Bcl-2 signals cancer cells to live longer.

14 Feb 2014

Researchers discover how beneficial bacteria in guts communicate with own cells

Communication is vital to any successful relationship. Researchers from the Institute of Food Research and the University of East Anglia have discovered how the beneficial bacteria in our guts communicate with our own cells.

14 Feb 2014

New study examines factors that may lead to end stage renal disease

About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease, at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure.

15 Jan 2014

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures.

5 Sep 2013